References
- Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010;28:1061–8.
- van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double- blind, placebo-controlled phase 3 trial. Lancet 2012;379: 1879–86.
- Kapadia S, Hapani S, Choueiri TK, Wu S. Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients. Acta Oncol 2013;52:1202–12.
- UK GlaxoSmithKline: Votrient 200 mg and 400 mg film coated tablets – Summary of Product Characteristics (SPC), electronic Medicines Compendium. [cited 2014 Nov 3]. Available from: http://www.medicines.org.uk/emc/medicine/23148/SPC/Votrient + 200 + mg+ and + 400 + mg+ film+ coated+ tablets/
- Westgeest HM, van Erp NP, Honeywell RJ, Hoekstra R, Peters GJ, Verheul HM. Successful treatment of renal cell carci- noma with sorafenib after effective but hepatotoxic sunitinib exposure. J Clin Oncol 2013;31:e83–6.
- Klempner SJ, Choueiri TK, Yee E, Doyle LA, Schuppan D, Atkins MB. Severe pazopanib-induced hepatotoxicity: Clinical and histologic course in two patients. J Clin Oncol 2012; 30:e264–8.
- Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D, et al. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer 2014;111: 1909–16.